Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review

Kruijff, Ingeborg E. de; Beije, Nick; Martens, John W.M.; Wit, Ronald de; Boormans, Joost L.; Sleijfer, Stefan

doi:10.1016/j.euo.2020.01.003

Cited by 21 publications

(18 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When compared to tissue biopsy, the liquid biopsy had the advantage of being easier to repeat over time in order to dynamically monitor disease progression (5). While liquid biopsies have shown potential in identifying MIBC patients for NAC, prospective trials investigating their true clinical applicability for therapy decision making are urgently needed (6,7).…”

Section: Introductionmentioning

confidence: 99%

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity

Xiao

Zhou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

PurposeTo investigate the role of circulating rare cells (CRCs), namely, circulating tumor cells (CTCs) and circulating endothelial cells (CECs), in aiding early intervention, treatment decision, and prognostication in bladder cancer.MethodsA total of 196 patients with pathologically confirmed bladder cancer, namely, 141 non-muscle invasive bladder cancer (NMIBC) and 55 muscle invasive bladder cancer (MIBC) patients. There were 32 patients who received cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Subtraction enrichment combined with immunostaining-fluorescence in situ hybridization (SE-iFISH) strategy was used for CTC/CEC detection. Kaplan–Meier analysis and Cox regression were used to evaluate the overall survival (OS) and recurrence-free survival (RFS). Receiver operator characteristic analysis was used to discriminate NAC sensitivity.ResultsCTCs and CECs were related to clinicopathological characteristics. Triploid CTCs, tetraploid CTCs, and total CECs were found to be higher in incipient patients than in relapse patients (P = 0.036, P = 0.019, and P = 0.025, respectively). The number of total CECs and large cell CECs was also associated with advanced tumor stage (P = 0.028 and P = 0.033) and grade (P = 0.028 and P = 0.041). Remarkably, tumor-biomarker-positive CTCs were associated with worse OS and RFS (P = 0.026 and P = 0.038) in NMIBC patients underwent TURBT. CECs cluster was an independent predictor of recurrence in non-high-risk NMIBC patients underwent TURBT (HR = 9.21, P = 0.040). For NAC analysis, pre-NAC tetraploid CTCs and small cell CTCs demonstrated the capability in discriminating NAC-sensitive from insensitive patients. Additionally, tetraploid CTCs and single CTCs elevated post-NAC would indicate chemoresistance.ConclusionCTCs and CECs may putatively guide in diagnosis, prognosis prediction, and therapeutic decision-making for bladder cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity

Xiao

Zhou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Several technologies for CTCs isolation and detection are based on negative selection of white blood cell membrane markers such as CD45 and positive selection using magnetic beads coupled to anti-epithelial cell adhesion molecule (EpCAM). Alternatively, employing immunofluorescence proprieties of CTCs to enrich for them, as the CellSearch method, is commonly utilized [ 55 ]. The detection rate of CTCs in localized MIBC is still relatively low, and only 30% of patients are CTC-positive [ 56 ].…”

Section: Platinum-based Chemotherapymentioning

confidence: 99%

“…Cirguidance (NTR4120) is currently recruiting MIBC RC candidates aiming to assess the patients without detectable CTCs (as a marker of good prognosis), in whom NAC administration can be omitted. The selected cut-off of CTCs is 1 with the primary endpoint of 2-years OS [ 55 ].…”

Section: Platinum-based Chemotherapymentioning

confidence: 99%

Molecular markers of systemic therapy response in urothelial carcinoma

Claps

Mir

Zargar

2021

Asian Journal of Urology

View full text Add to dashboard Cite

Identification of reliable molecular biomarkers that can complement clinical practice represents a fascinating challenge in any cancer field. Urothelial carcinoma is a very heterogeneous disease and responses to systemic therapies, and outcomes after radical cystectomy are difficult to predict. Advances in molecular biology such as next generation sequencing and whole genome or transcriptomic analysis provide promising platforms to achieve a full understanding of the biology behind the disease and can identify emerging predictive biomarkers. Moreover, the ability to categorize patients' risk of recurrence after curative treatment, or even predict benefit from a conventional or targeted therapies, represents a compelling challenge that may reshape both selection for tailored treatment and disease monitoring. Progress has been made but currently no molecular biomarkers are used in the clinical setting to predict response to systemic agents in either neoadjuvant or adjuvant settings highlighting a relevant unmet need. Here, we aim to present the emerging role of molecular biomarkers in predicting response to systemic agents in urothelial carcinoma.

show abstract

“…Patients with muscleinvasive bladder cancer (MIBC) present high incidence of metastasis and poor prognosis. Therefore, for MIBC patients it is urgent to find biomarkers for early diagnosis and to follow the progression of the disease during active surveillance by liquid biopsy (de Kruijff et al, 2020). Very recently a novel circRNA, circ lysophosphatidic acid receptor 1 (LPAR1) (hsa_circ_0087960), derived from two exons of 226 base pairs in length, has been identified in MIBC tissues ( Table 3).…”

Section: Circrnas In Muscle-invasive Cancersmentioning

confidence: 99%

Circular RNAs in Embryogenesis and Cell Differentiation With a Focus on Cancer Development

Agostino¹,

Riccioli

Cesaris

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

In the recent years thousands of non-coding RNAs have been identified, also thanks to highthroughput sequencing technologies. Among them, circular RNAs (circRNAs) are a well-represented class characterized by the high sequence conservation and cell type specific expression in eukaryotes. They are covalently closed loops formed through back-splicing. Recently, circRNAs were shown to regulate a variety of cellular processes functioning as miRNA sponges, RBP binding molecules, transcriptional regulators, scaffold for protein translation, as well as immune regulators. A growing number of studies are showing that deregulated expression of circRNAs plays important and decisive actions during the development of several human diseases, including cancer. The research on their biogenesis and on the various molecular mechanisms in which they are involved is going very fast, however, there are still few studies that address their involvement in embryogenesis and eukaryotic development. This review has the intent to describe the most recent progress in the study of the biogenesis and molecular activities of circRNAs providing insightful information in the field of embryogenesis and cell differentiation. In addition, we describe the latest research on circRNAs as novel promising biomarkers in diverse types of tumors.

show abstract

Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review

Cited by 21 publications

References 55 publications

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity

Molecular markers of systemic therapy response in urothelial carcinoma

Circular RNAs in Embryogenesis and Cell Differentiation With a Focus on Cancer Development

Contact Info

Product

Resources

About